Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Duke University Medical Center, Durham, NC, United States



Survival: 2.9 months
   
Toxicity Grade: 3
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Durham, NC
   
Hospital: Duke University Medical Center
   
Journal: Link
   
Date: 9/2010

Description:
Patients:
This study involved a total of 23 glioblastoma multiforme patients who had progressed following previous treatment with bevacizumab. Patients were separated into 2 separate treatment groups. Group A consisted of 10 patients with a median age of 50.8 years and 70% male. Group B was made up of 13 patients with a median age of 52.4 years and 85% male.

Treatment:
Patients in group A were treated with the chemotherapeutic agent temozolomide and the biologic therapy agent bevacizumab, which is a monoclonal antibody that blocks cancer cell growth by targeting the vascular endothelial growth factor (VEGF) protein.

Patients in group B were treated with the chemotherapeutic agent etoposide and the biologic therapy agent bevacizumab.

Toxicities:
The highest toxicity in group A was of grade 3, which was 1 case of grade 3 infection. In group B, there was 1 grade 4 toxicity reported, which was a case of neutropenia. Patients in this group also reported grade 2 and 3 fatigue (4 patients).

Results:
Median overall survival in group A was 12.6 weeks (2.9 months). For group B, the median overall survival was 19.0 weeks (4.4 months).

Support:
This study was partially supported by Genentech Pharmaceuticals, makers of Avastin (trade name for bevacizumab).

Correspondence: Dr. David A. Reardon; email: reard003@mc.duke.edu

E-mail to a Friend Email Physician More Information